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Abstract
On January 30, 2020, the COVID-19 epidemic was declared an international public health emergency by the World
Health Organization. Given the growing impact of the pandemic, there is great interest in ﬁnding potential targets for
treating infected or hospitalized COVID-19 patients. Therapeutic studies have been conducted on pre-existing drugs,
which vary by country, including anti-malarial agents, antiviral agents, and convalescent plasma. However, many of
these agents are ineffective at reducing mortality or only shorten the severity or duration of COVID-19 illness in hospitalized patients. As such, other alternatives for treating COVID-19 are being investigated. One such target of interest
has been clathrin-dependent endocytosis (CDE). Clathrin-dependent endocytosis is the most commonly observed
mechanism of viral entry into cells. However, there have been no published studies to date on CDE inhibition strategies
against COVID-19. One such target is Rlip or RLIP76 (human gene RALBP1, 18p11.22). Among its many functions, Rlip
is a stress-protective, Ral-regulated ATPase of the mercapturic acid pathway that transports glutathione-electrophile
conjugates of electrophilic toxins, which are precursors of mercapturic acid that precedes de-glutamylation by gammaglutamyl transferase. Rlip is also regulated by several G-proteins that coordinate movement of cells, organelles,
membranes, cytoskeleton, macromolecules, and other small molecules. Previous studies have link Rlip in the pathogenesis of several viral illness. In this paper, we want to propose that RLIP76 (Rlip or RALBP1) may be a novel target for
treating SARS-CoV-2 viral infections.
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1. Introduction

O

n January 30, 2020, the COVID-19 epidemic
was declared an international public health
emergency by the World Health Organization.
Currently, the SARS-CoV-2 virus has infected over
72 million and killed over 1.5 million people
worldwide. Given the growing impact of the
pandemic, there is great interest in ﬁnding potential
cell-surface receptor targets for treating infected
or hospitalized COVID-19 patients. Therapeutic
studies have been conducted on pre-existing drugs,
which vary by country, including antiviral agents
and convalescent plasma.1 However, many of these
agents are ineffective and do note reduce the mortality or only shorten the severity or duration of
COVID-19 illness in hospitalized patients. As such,
other alternatives for treating COVID-19 are being

investigated. One such target of interest has been
clathrin-dependent endocytosis (CDE).
Clathrin-dependent endocytosis is the most
commonly observed mechanism of viral entry into
cells.2 After a viral particle attaches to the plasma
membrane surface, the virus is internalized into
endosomes and transported to either the plasma
membrane/secretory pathway or the late endosomes to be degraded in lysosomes.3 This pathway
has important roles in the infections of several viruses, including coronaviruses, inﬂuenza A virus,
rhinovirus, and adenovirus 2.3,4 Speciﬁcally, clathrin-dependent endocytosis and cathepsin- mediated S protein cleavage are two important steps for
viral entry and pathogenesis of SARS-CoV-2.3,5
Several coronaviruses have been reported to utilize
CDE for viral internalization, including the Middle
East respiratory syndrome (MERS) virus,6 the
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mouse hepatitis coronavirus (MHC),7 and the original SARS coronavirus which utilizes the ACE2 receptor for entry.8 The SARS-CoV-2 (COVID-19)
coronavirus also utilizes the ACE2 receptor9 and
likely uses CDE for viral internalization. A recent
study showed that the top canonical pathways
associated with plasma ACE2 included clathrinmediated endocytosis signaling, actin cytoskeleton
signaling, EIF2 (eukaryotic initiation factor 2)
signaling, and the protein ubiquitination pathway.10
However, there have been no published studies to
date on CDE inhibition strategies against COVID19. In this paper, we want to propose that RLIP76
(Rlip or RALBP1) may be a novel target for treating
SARS-CoV-2 viral infections.

2. SARS-CoV-2 and endocytosis
The COVID-19 pandemic has left the world in a
distressful situation. Treatments are primarily based
on supportive care or on drugs with uncertain efﬁcacies, and a lack of strong preclinical evidence
makes it difﬁcult to predict the efﬁcacy of the
vaccination strategies under development.11 Therefore, the need for the safe and effective pharmacologic therapies is greater than ever. Clathrindependent endocytosis (CDE) is the most commonly
observed mechanism of viral entry into cells.2
SARS-CoV-2 virus binds to the human angiotensin
converting enzyme 2 (ACE2) receptor and the neuropillin receptor using viral spike glycoproteins to
gain entry into vulnerable cells via CDE.12,13 Neuropilin is known to initiate endocytosis.14 Several
other studies have shown that the Moesin receptor,
an actin anchoring membrane-organizing protein, is
also involved in the pathogenesis of the measles,
human immunodeﬁciency virus (HIV), and herpes
simplex viruses.15e22 It is hypothesized that Moesin
negatively regulates stable microtubule networks,
which determines cellular sensitivity to retroviral
infection.23 However, we argue that another regulator of endocytosis, known as Rlip, may be a potential therapeutic target for COVID-19.

3. Rlip and endocytosis
RLIP76 (Rlip or RALBP1) is a multifunctional
membrane ATPase that links the mercapturic acid
pathways to clathrin-dependent endocytosis (CDE).
RLIP76 (Rlip), the 76KDa product of the RalA
Binding Protein 1 (RALBP1) gene, is critical for the
completion of clathrin-dependent endocytosis.24e26
Rlip serves as a scaffold for the formation of endocytic complexes during interphase and regulates
endocytosis.25,27e29 Rlip knockout mice have

severely deﬁcient CDE resulting in impaired internalization of receptor-ligand complexes. These mice
show improved insulin-sensitive, hypoglycemic,
hypolipidemic, and concomitantly markedly resistant to obesity and either chemically induced or
spontaneous carcinogenesis that accompanies p53
loss.30 They also have remarkably low levels of
numerous inﬂammatory cytokines.
RNA-Seq and whole-genome bisulﬁte sequencing
studies show that biological processes and signaling
pathways that govern viral entry, signaling by TNF,
IL-6, and chemokine as well as Ral- and Rho-regulated intracellular trafﬁcking are inhibited.31e33
Interestingly, there is considerable overlap between
Rlip-interacting pathways and moesin, a human
spike protein that functions as an actin anchor and
membrane-organizing protein for endocytic trafﬁcking of the EGF receptor and the RhoA signaling
pathways that have been implicated in SARS virus
endocytosis. Using RNA sequencing (RNAseq) data
from heterozygous or homozygous depleted mice,
we show a highly overlapping interaction network
between Rlip and moesin. The network has 229
intersecting nodes of protein-coding and miRNAs
genes and Rlip depletion inhibits several nodes
important for viral infection, diabetes and cancer
with down-regulation and multiple key nodes by
Rlip depletion.
These ﬁndings were supported by proteomic analyses of spleen from Rlip / mice showing reduction in the quantity of multiple proteins that are
upstream regulators of RNA virus infection per the
Ingenuity Pathway Analysis software (Figs. 1e3).
Several proteins in this network are directly related
to the pathogenesis of other viral infections. The
CTSB gene encodes a lysosomal cysteine protease,
known as Cathepsin B, which facilitates chikungunya virus infectivity via endocytosis or micropinocytosis.34 Another study found that Cathepsin B
facilitated CD4-independent entry of HIV-1 through
endocytosis and endosomal acidiﬁcation processes.35 The ANXA2 gene, which encodes annexin
II, is a multifunctional calcium- and lipid-binding
protein that contributes to the pathogenesis of
several viruses (e.g., human papillomavirus, cytomegalovirus, and the inﬂuenza A virus) through
actin remodeling near the plasma membrane.36,37
This actin remodeling subsequently inﬂuences
endocytosis processes, particularly CDE.36,37 However, many of the targets suggested by the network
analysis have not been directly linked to endocytosis
and viral pathogenesis.
Therefore, investigating Rlip function with respect
to viral infections may describe additional

91
RESEARCH ARTICLE

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES 2022;12:89e94

Fig. 1. Upstream regulators of RNA virus infection. Results are from IPA analyses of Rlip / C57-Bl/6 mice spleen proteomic analyses normalized to
wild-type. Green represents down-regulation and red represents up-regulation. Several proteins (e.g., CTSB) in this network are directly related to the
pathogenesis of other viral infections.

mechanisms by which it regulates CDE. Several
studies demonstrate the functional importance of
heptad repeats of the SARS-CoV spike protein in
membrane fusion and viral entry.38 Using the online
tool (http://coiledcoils.chm.bris.ac.uk/Scorer/) we
found RalBP1 has long C-terminal heptad repeats. It
is yet to be established the functional interactive role
of heptad repeats of these two key proteins involved
in internalization of coronavirus. Further, hyperglycemia may inﬂuence the glycosylation patterns
on ACE2 and the viral spikes resulting in increased
binding afﬁnity.39 Research into the mouse hepatitis
coronavirus suggests that after internalization,
coronaviruses may spread via direct cell-to-cell fusions requiring functional macropinocytosis, an
actin-mediated nonspeciﬁc uptake mechanism.40
Thus, targeting Rlip76 (a protein product of
RALBP1) may inhibit the successful internalization
of coronaviruses into cells by stalling endocytosis
and by lowering plasma glucose levels to reduce the
viral sugar coating necessary for attachment to the
cell surface. Therefore, we predict that therapies

targeting this pathway may help reduce viral entry
into vulnerable cells. Using the results from this
analysis, we propose that there may be beneﬁt in
targeting these genes and proteins in the treatment
of COVID-19 with regards to Rlip and endocytosis
inhibition. However, there are currently no
approved inhibitors for Rlip in humans. We have
recently shown that the naturally occurring and
non-toxic orange peel-derived compound 2’hydroxyﬂavanone that inhibits both endocytosis
and cancer growth, particularly in lung cancer.41
Speciﬁcally, 2’-hydroxyﬂavanone effectively inhibits
the transport and endocytic functions of Rlip.42 2'hydroxyﬂavanone (2HF) is highly tolerable and is
considered generally regarded as safe by the
FDA.41,42
Furthermore, 2HF is also capable of inhibiting
micropinocytosis.42 In vitro studies have shown that
the inhibition of macropinocytosis reduces MHC viral
titers.40 In addition, viral activation of macropinocytosis was found to be dependent on EGF receptor activation.40 Recently, a clinical trial in Spain
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Fig. 2. Effect of Rlip loss on COVID-19 pathogenesis pathway. The red geometric shape indicates an increase in measurement. The green
geometric shape indicates a decrease in measurement. The orange geometric shape indicates an increase in prediction of the activity of connected
signaling node. The blue geometric node indicates a decrease in prediction of the activity of connected signaling node. The glow around a geometric
shape indicates activity when opposite of measurement. The orange line indicates an interaction leading to activation. The blue line indicates an
interaction leading to inhibition. The yellow line indicates ﬁndings inconsistent with state of downstream molecule. The grey line indicates effect not
predicted.

has begun recruiting subjects to investigate whether
combining ruxolitinib with simvastatin may both
prevent and treat respiratory failure of in hospitalized
COVID-19 patients (ClinicalTrials.gov Identiﬁer:
NCT04348695). Similarly, 2’-hydroxyﬂavanone could
be investigated in randomized clinical trials alone or
with other treatment regimens to assess whether 2HF
would be effective at reducing the morbidity or mortality in hospitalized COVID-19 patients. For these
reasons, our primary hypothesis is that inhibition of
Rlip will inhibit the successful internalization of
coronaviruses into cells, resulting in reduced viral titer
and reduced severity of symptoms.

4. Pitfalls, limitations, and alternative
strategies
It is possible that the COVID-19 virus does not
require the completion of the clathrin-dependent
endocytosis process for viral entry into certain types
of cells. In this case RLIP inhibition may not be
effective against COVID-19 since loss of RLIP stalls
endocytosis relatively late in the process. It is also
possible that blocking clathrin-dependent viral entry
is insufﬁcient to completely abrogate entry, as clathrin-independent viral entry has also been reported
for the original SARS virus in HEK293E cells.43
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Fig. 3. Effect of Rlip heterozygous loss on viral entry pathway. The red geometric shape indicates an increase in measurement. The green
geometric shape indicates a decrease in measurement. The orange geometric shape indicates an increase in prediction of the activity of connected
signaling node. The blue geometric node indicates a decrease in prediction of the activity of connected signaling node. The glow around a geometric
shape indicates activity when opposite of measurement. The orange line indicates an interaction leading to activation. The blue line indicates an
interaction leading to inhibition. The yellow line indicates ﬁndings inconsistent with state of downstream molecule. The grey line indicates effect not
predicted
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